196 related articles for article (PubMed ID: 17264944)
1. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis.
de Bruijne EL; Darwish Murad S; de Maat MP; Tanck MW; Haagsma EB; van Hoek B; Rosendaal FR; Janssen HL; Leebeek FW;
Thromb Haemost; 2007 Feb; 97(2):181-5. PubMed ID: 17264944
[TBL] [Abstract][Full Text] [Related]
2. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis.
Martini CH; Brandts A; de Bruijne EL; van Hylckama Vlieg A; Leebeek FW; Lisman T; Rosendaal FR
Br J Haematol; 2006 Jul; 134(1):92-4. PubMed ID: 16803573
[TBL] [Abstract][Full Text] [Related]
3. Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis.
Franco RF; Fagundes MG; Meijers JC; Reitsma PH; Lourenço D; Morelli V; Maffei FH; Ferrari IC; Piccinato CE; Silva WA; Zago MA
Haematologica; 2001 May; 86(5):510-7. PubMed ID: 11410415
[TBL] [Abstract][Full Text] [Related]
4. Haplotypes of TAFI gene and the risk of cerebral venous thrombosis--a case-control study.
Orikaza CM; Morelli VM; Matos MF; Lourenço DM
Thromb Res; 2014 Jan; 133(1):120-4. PubMed ID: 24252537
[TBL] [Abstract][Full Text] [Related]
5. Association of genotypes of thrombin-activatable fibrinolysis inhibitors with thrombotic microangiopathies--a pilot study.
Sucker C; Hetzel GR; Farokhzad F; Dahhan F; Schmitz M; Kurschat C; Grabensee B; Maruhn-Debowski B; Zotz R; Scharf R
Nephrol Dial Transplant; 2007 May; 22(5):1347-50. PubMed ID: 17327284
[TBL] [Abstract][Full Text] [Related]
6. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease].
Xu CW; Wang LL; Wu XB; Zhao JJ; Du YM; Jiang CY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):438-42. PubMed ID: 18683146
[TBL] [Abstract][Full Text] [Related]
7. Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome.
Tàssies D; Roqué M; Monteagudo J; Martorell T; Sionis A; Arzamendi D; Heras M; Reverter JC
Thromb Res; 2009 Nov; 124(5):614-8. PubMed ID: 19699511
[TBL] [Abstract][Full Text] [Related]
8. Thrombin-activatable fibrinolysis inhibitor polymorphisms and recurrent pregnancy loss.
Masini S; Ticconi C; Gravina P; Tomassini M; Pietropolli A; Forte V; Federici G; Piccione E; Bernardini S
Fertil Steril; 2009 Aug; 92(2):694-702. PubMed ID: 18774564
[TBL] [Abstract][Full Text] [Related]
9. Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation.
Ladenvall C; Gils A; Jood K; Blomstrand C; Declerck PJ; Jern C
Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):955-62. PubMed ID: 17272741
[TBL] [Abstract][Full Text] [Related]
10. Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study.
Kozian DH; Lorenz M; März W; Cousin E; Mace S; Deleuze JF
Thromb Haemost; 2010 May; 103(5):976-83. PubMed ID: 20216989
[TBL] [Abstract][Full Text] [Related]
11. The association of the JAK2 46/1 haplotype with non-splanchnic venous thrombosis.
Zerjavic K; Zagradisnik B; Lokar L; Krasevac MG; Vokac NK
Thromb Res; 2013 Aug; 132(2):e86-93. PubMed ID: 23845539
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in the TAFI gene and the risk of venous thrombosis.
Kostka H; Kuhlisch E; Schellong S; Siegert G
Clin Lab; 2003; 49(11-12):645-7. PubMed ID: 14651335
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
Ricart JM; Ramón LA; Vayá A; España F; Santaolaria ML; Todolí J; Castelló R; Fontcuberta J; Estellés A
Br J Haematol; 2008 May; 141(5):716-9. PubMed ID: 18341631
[TBL] [Abstract][Full Text] [Related]
14. +1040 C/T polymorphism in coding region of thrombin-activatable fibrinolysis inhibitor gene and the risk of idiopathic recurrent fetal loss.
Pruner I; Djordjevic V; Miljic P; Kovac M; Antonijevic N; Rakicevic L; Radojkovic D
Blood Coagul Fibrinolysis; 2010 Oct; 21(7):679-82. PubMed ID: 20729722
[TBL] [Abstract][Full Text] [Related]
15. Thrombin activatable fibrinolysis inhibitor and clot lysis time in pregnant patients with antiphospholipid syndrome: relationship with pregnancy outcome and thrombosis.
Martinez-Zamora MA; Tassies D; Carmona F; Espinosa G; Cervera R; Reverter JC; Balasch J
Am J Reprod Immunol; 2009 Dec; 62(6):381-9. PubMed ID: 19895374
[TBL] [Abstract][Full Text] [Related]
16. The 1040C/T polymorphism influencing thermal stability and activity of thrombin activatable fibrinolysis inhibitor is associated with risk for oral cancer.
Vairaktaris E; Yapijakis C; Nkenke E; Vassiliou S; Vylliotis A; Nixon AM; Derka S; Ragos V; Spyridonidou S; Tsigris C; Neukam FW; Patsouris E
Am J Hematol; 2007 Nov; 82(11):1010-2. PubMed ID: 17636471
[TBL] [Abstract][Full Text] [Related]
17. Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer.
Chengwei X; Xiaoli M; Yuan Z; Li P; Shengjiang W; Chao Y; Yunshan W
Blood Coagul Fibrinolysis; 2013 Oct; 24(7):698-703. PubMed ID: 23624357
[TBL] [Abstract][Full Text] [Related]
18. ABO blood group but not haemostasis genetic polymorphisms significantly influence thrombotic risk: a study of 180 homozygotes for the Factor V Leiden mutation.
Procare-GEHT Group
Br J Haematol; 2006 Dec; 135(5):697-702. PubMed ID: 17107352
[TBL] [Abstract][Full Text] [Related]
19. Haplotypes of IL1B, IL1RN, IL1R1, and IL1R2 and the risk of venous thrombosis.
van Minkelen R; de Visser MC; Houwing-Duistermaat JJ; Vos HL; Bertina RM; Rosendaal FR
Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1486-91. PubMed ID: 17413037
[TBL] [Abstract][Full Text] [Related]
20. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases.
Saibeni S; Bottasso B; Spina L; Bajetta M; Danese S; Gasbarrini A; de Franchis R; Vecchi M
Am J Gastroenterol; 2004 Oct; 99(10):1966-70. PubMed ID: 15447757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]